Navigation Links
ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104

CLEVELAND, March 25 /PRNewswire/ -- ChanTest, the leading provider of ion channel testing services for drug-discovery and development applications, will feature at the SBS conference the company's expanding line of ion channel services designed to give drug-discovery researchers the early information they need to identify the most promising compounds, and eliminate those that could be harmful -- before they invest millions in the drug-development process. The 14th Annual Society for Biomolecular Sciences (SBS) Conference takes place April 6-10, 2008, at the America's Center Convention Complex in St. Louis, Missouri. ChanTest is exhibiting in booth 1104.

"When completed early in the drug-discovery process, ChanTest's functional ion channel screens can save considerable time, money, and other resources," said Dr. Arthur (Buzz) Brown, founder and CEO of ChanTest. "Our automated and manual patch clamp profiling screens provide more-accurate results than binding screens since results are generated by measuring the functional effects of drugs directly on ion channel currents. For higher-throughput screening, we use FLIPRTetra(R) to measure membrane potential and potassium flux for voltage-gated and calcium-activated potassium channels. Too often, researchers identify unacceptable safety risks late in the drug-development process -- during the GLP (Good Laboratory Practices) patch-clamp studies that are required by the FDA for an IND (Investigational New Drug) submission. Using our functional screens during the discovery profiling process helps avoid this situation."

Dr. Brown continued, "Unlike most service organizations, ChanTest has validated its cell lines for testing at each phase of the drug-discovery process. Whether customers need initial high-throughput screening of hits, high-sensitivity screens for lead identification and lead optimization, or safety testing in preparation for an IND submission -- our results will correlate. We tailor each customer's service program to meet their discovery and budgetary goals. We're proud of the reputation we've built over the past 10 years -- delivering fast, accurate, and reliable results on thousands of compounds to pharmaceutical and biotechnology customers worldwide. We don't just deliver raw data -- our ion channel experts tell customers what the results mean."

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines -- the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 12,000 compounds for more than 250 global pharmaceutical and biotech companies -- helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
2. Helix BioPharma reports Q2 2008 highlights, financial results
3. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
4. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
5. MEDEA+ Noblanc award highlights improvements in microelectronics
6. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
7. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
8. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
9. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
10. Oncothyreon highlights corporate and clinical objectives for 2008
11. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
Post Your Comments:
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):